• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ovarian cancer screening.

作者信息

Urban Nicole, McIntosh Martin W, Andersen Marin, Karlan Beth Y

机构信息

Cancer Prevention Research Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, MP-900, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA.

出版信息

Hematol Oncol Clin North Am. 2003 Aug;17(4):989-1005, ix. doi: 10.1016/s0889-8588(03)00063-7.

DOI:10.1016/s0889-8588(03)00063-7
PMID:12959188
Abstract

In an ongoing effort to design an efficacious, cost-effective ovarian cancer screening method, the existing tests, CA 125 and transvaginal sonography, are being optimized and combined in a multimodal strategy, and new promising serum markers, such as mesothelin and HE4, are being developed and evaluated. Detection has been found to improve when multiple serum markers are used in a longitudinal logarithm. The parametric empirical Bayes approach improves screening algorithms by capturing the stability of markers over time in a heterogeneous population. It also has relatively simple extensions to multiple markers. The evaluation of markers increasingly accounts for characteristics of a woman that may affect her marker levels and accounts for the cancer's characteristics, histology, and grade. Receiver operating characteristic curves are helpful for evaluation because they relate a marker's sensitivity to the specificity at which it operates. Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods.

摘要

相似文献

1
Ovarian cancer screening.
Hematol Oncol Clin North Am. 2003 Aug;17(4):989-1005, ix. doi: 10.1016/s0889-8588(03)00063-7.
2
Elevation of multiple serum markers in patients with stage I ovarian cancer.I期卵巢癌患者多种血清标志物升高。
J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51. doi: 10.1093/jnci/85.21.1748.
3
Combined use of biomarkers for detection of ovarian cancer in high-risk women.联合使用生物标志物检测高危女性的卵巢癌
Tumour Biol. 2010 Jun;31(3):209-15. doi: 10.1007/s13277-010-0032-x.
4
New tumor markers: CA125 and beyond.新型肿瘤标志物:CA125及其他。
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. doi: 10.1111/j.1525-1438.2005.00441.x.
5
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.使用多元正态分布混合模型联合癌抗原CA-125II、CA 15-3、CA 72-4和巨噬细胞集落刺激因子时,早期卵巢癌的术前敏感性和特异性。
J Clin Oncol. 2004 Oct 15;22(20):4059-66. doi: 10.1200/JCO.2004.03.091. Epub 2004 Sep 20.
6
Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.血清HE4、CA125、CA72-4及ROMA指数在卵巢癌诊断及术后复发预测中的临床价值
Clin Lab. 2019 Apr 1;65(4). doi: 10.7754/Clin.Lab.2018.181030.
7
Status of tumor markers in ovarian cancer screening.肿瘤标志物在卵巢癌筛查中的现状。
J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s. doi: 10.1200/JCO.2003.01.068.
8
Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.开发一种多标志物检测方法用于鉴别诊断良恶性盆腔包块。
Clin Chim Acta. 2015 Feb 2;440:57-63. doi: 10.1016/j.cca.2014.11.013. Epub 2014 Nov 15.
9
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.联合多种血清肿瘤标志物可提高I期上皮性卵巢癌的检测率。
Gynecol Oncol. 2007 Dec;107(3):526-31. doi: 10.1016/j.ygyno.2007.08.009. Epub 2007 Oct 24.
10
CA125 and HE4: Measurement Tools for Ovarian Cancer.CA125与HE4:卵巢癌的检测工具
Gynecol Obstet Invest. 2016;81(5):430-5. doi: 10.1159/000442288. Epub 2016 Apr 29.

引用本文的文献

1
The diagnostic performance of the Mindray system in detecting CA125 and HE4 for patients with ovarian cancer.迈瑞系统在检测卵巢癌患者CA125和HE4方面的诊断性能。
Transl Cancer Res. 2024 Aug 31;13(8):4474-4484. doi: 10.21037/tcr-24-1107. Epub 2024 Aug 21.
2
Comparison of the diagnostic efficacy of systemic inflammatory indicators in the early diagnosis of ovarian cancer.全身炎症指标在卵巢癌早期诊断中的诊断效能比较。
Front Oncol. 2024 Jul 2;14:1381268. doi: 10.3389/fonc.2024.1381268. eCollection 2024.
3
Demons-Meigs syndrome caused by a giant ovarian fibroma: A case report.
巨大卵巢纤维瘤所致梅格斯综合征:一例报告
Radiol Case Rep. 2024 Apr 13;19(7):2585-2589. doi: 10.1016/j.radcr.2024.03.016. eCollection 2024 Jul.
4
Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.中国及全球卵巢癌的液体活检:现状与未来展望
Front Oncol. 2023 Dec 19;13:1276085. doi: 10.3389/fonc.2023.1276085. eCollection 2023.
5
Survival prognosis model for elderly women with epithelial ovarian cancer based on the SEER database.基于监测、流行病学和最终结果(SEER)数据库的老年上皮性卵巢癌女性生存预后模型
Front Oncol. 2023 Sep 29;13:1257615. doi: 10.3389/fonc.2023.1257615. eCollection 2023.
6
Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses.CA125、HE4 和全身免疫炎症指数在卵巢肿块术前检查中的诊断价值。
Medicine (Baltimore). 2023 Sep 15;102(37):e35240. doi: 10.1097/MD.0000000000035240.
7
Ovarian Cancer Biomarkers in the COVID-19 Era.COVID-19 时代的卵巢癌生物标志物。
Int J Environ Res Public Health. 2023 May 29;20(11):5994. doi: 10.3390/ijerph20115994.
8
Osteopontin as a Tumor Marker in Ovarian Cancer.骨桥蛋白作为卵巢癌的肿瘤标志物
J Midlife Health. 2022 Jul-Sep;13(3):200-205. doi: 10.4103/jmh.jmh_52_22. Epub 2023 Jan 14.
9
A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer.一种基于双生物标志物TK1蛋白和CA125或HE4的算法,作为比ROMA指数更好的诊断工具用于卵巢癌的早期检测。
Cancers (Basel). 2023 Mar 3;15(5):1593. doi: 10.3390/cancers15051593.
10
Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma.HE4组织表达在浆液性上皮性卵巢癌中的预后意义
South Asian J Cancer. 2022 Feb 27;11(2):125-132. doi: 10.1055/s-0042-1742711. eCollection 2022 Apr.